The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspecs Group Regulatory News (SPEC)

Share Price Information for Inspecs Group (SPEC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 56.00
Bid: 55.00
Ask: 57.00
Change: -1.00 (-1.75%)
Spread: 2.00 (3.636%)
Open: 57.00
High: 57.00
Low: 56.00
Prev. Close: 57.00
SPEC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Board Changes

27 Oct 2022 07:00

RNS Number : 2536E
Inspecs Group PLC
27 October 2022
 

27 October 2022

 

Inspecs Group plc

 

("Inspecs" or "the Group")

 

Trading Update and Board Changes

 

Inspecs Group plc, a global eyewear and lens design house and manufacturer, today announces a trading update for the 9 months to 30 September 2022 (the "Period") and provides a full year outlook.

On a constant currency basis, the Group has seen sales growth across Europe, UK and the US during the Period, as well as in the Group's manufacturing businesses in Vietnam and China. As set out in the Group's Interim Results, this growth has been impacted by unfavourable foreign exchange movements, particularly with the Euro weakening against the US dollar. Revenue for the Period in both reported and constant currency is set out below:

 

Revenue: reported currency

US$m

9 months to

30-Sept-22

9 months to

30-Sept-21

 Change

Group

179.4

185.0

-3.0%

Acquisitions during December 2021

10.8

-

-

Total

190.2

185.0

+2.8%

 

 

Revenue: constant currency1:

US$m

9 months to

30-Sept-22

9 months to

30-Sept-21

Change

Group

191.8

185.0

+3.7%

Acquisitions during December 2021

11.2

-

-

Total

203.0

185.0

+9.8%

 

1

Constant exchange rates: figures at constant exchange rates have been calculated using the average exchange rates in effect for the relevant comparative period.

 

In Europe, in particular Germany, both the macro-economic climate and consumer confidence have deteriorated sharply since September 2022. German consumer confidence is now at a 25-year low and this is reflected in the order intake that is significantly down on the previous year. The Group's expectation is that the German and French markets will remain weak into the first half of 2023.

 

In the US, the order book remains at a similar level to the prior year whilst in the UK, the Group's frame business has shown growth on the previous year. The Group's Vietnamese and Chinese manufacturing business, which is affected by the European market, has seen a decrease in its order book. Overall, the Group order book is down 13% at 30-Sept-22 on the previous year.

 

Due to the reduced order book, the Board has decided to delay the expansion of the existing Vietnamese factory and the investment in a new factory in Portugal until at least Q3 2023.

 

As set out in the Group's Interim Results, it took longer than expected to complete Norville's new state-of-the-art manufacturing facility, but the investment is still expected to deliver a return in 2023. The factory is working with the Group's "Skunk Works" to continue developing ground breaking lens technology for smart eyewear, along with other revolutionary lens-related projects.

 

 

Board changes and finance function

 

Lord MacLaurin has notified the Board of his intention to retire as Chairman on 1 December 2022. His contribution throughout his tenure has been invaluable to the Group. As a result, Robin Totterman, CEO and founder of Inspecs, will move to an Executive Chairman role from 1 December 2022. Simultaneously, Richard Peck, current non-executive Director, and previously MD of Luxottica Retail northern Europe and MD of David Clulow, will become the Group's Chief Executive Officer.

 

The Board is currently in advanced stages of the take on process to appoint two new additional non-executive directors to the Board, and an update will be provided in due course.

 

With regards the Group's finance function, Inspecs is pleased to announce that Matthew Loran will join the Group as its new Group Finance Manager in November 2022. Matthew previously worked for Capita Group plc and Imperial Brands plc, working with the divisional finance teams around the globe. His experience will assist the Group as it continues to expand and integrate its accounting functions. In addition, new accounting personal have been recruited in both the Group's German and USA subsidiaries to enhance reporting and controls.

 

Outlook

 

It is clear that Inspecs is not immune to the macro environment or the downturn in consumer confidence, particularly in Europe, and this is expected to impact the remainder of this year and into the first half of 2023. That said, Inspecs continues to increase its market share and the Group is well placed to return to growth as and when its core markets return.

 

The Board will provide a Full Year trading update in January 2023 when it will look to give further guidance on the outturn for 2022 and the year ahead.

 

 

For further information please contact:

 

Inspecs Group plc

Robin Totterman (CEO)

Chris Kay (CFO)

 

via FTI Consulting

Tel: +44 (0) 20 3727 1000

Peel Hunt (Nominated Adviser and Broker)

Adrian Trimmings

Andrew Clark

Lalit Bose

Tel: +44 (0) 20 7418 8900

 

 

FTI Consulting (Financial PR)

Alex Beagley

Harriet Jackson

Alice Newlyn

 

Tel: +44 (0) 20 3727 1000

This announcement contains inside information for the purposes of the Market Abuse Regulation (Regulation (EU) No 596/2014) including as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018. The person responsible for arranging release of this announcement on behalf of Inspecs is Chris Kay, Chief Financial Officer.

 

 

About Inspecs Group plc

 

INSPECS is a Bath-based designer, manufacturer and distributor of eyewear frames and optically advanced spectacle lenses. The Group produces a broad range of frames and lenses, covering optical, sunglasses and safety, which are either "Branded" (either under licence or under the Group's own proprietary brands), or "OEM" (including private label on behalf of retail customers as well as unbranded).

 

INSPECS aims to be the leader in eyewear solutions through its vertically-integrated business model and has adopted a three-pillar growth strategy to achieve this: (i) continue to grow organically; (ii) undertake further acquisitions (and drive value through leveraging the Group's internal capabilities); and (iii) extend the Group's manufacturing capacity.

 

The Group has completed several significant acquisitions since its IPO in February 2020. In December 2020, INSPECS acquired Eschenbach, a leading global eyewear supplier, headquartered in Nuremberg, Germany, which includes the American company Tura. This followed the acquisition of lens maker Norville in July 2020, whereby INSPECS combined two British heritage brands, Savile Row frame maker, and Norville lens maker, further enhancing its vertically-integrated business model. In December 2021 the Group acquired Ego Eyewear, a design and licensing company which uses third party eyewear manufacturers to produce premium fashion brands, and BoDe, a distributor of optical frames and sunglasses principally to the German and neighbouring markets. 

INSPECS customers include global optical and non-optical retailers, global distributors and independent opticians, with its distribution network covering over 80 countries and reaching approximately 75,000 points of sale.

INSPECS has operations across the globe: with offices and subsidiaries in the UK, Germany, Portugal, Scandinavia, the US and China (including Hong Kong, Macau and Shenzhen), and manufacturing facilities in Vietnam, China, the UK and Italy. With the acquisition of Eschenbach, the Group's international reach further extends across Europe and the American markets.

More information is available at: https://inspecs.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANEKAAPAFFA
Date   Source Headline
23rd Apr 20243:57 pmRNSHolding(s) in Company
19th Apr 20249:35 amRNSHolding(s) in Company
17th Apr 20247:00 amRNSFinal Results
29th Jan 20247:00 amRNSFull Year Trading Update
11th Jan 20242:10 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSTrading Update
20th Sep 202311:14 amRNSHolding(s) in Company
7th Sep 20237:00 amRNSInterim Results
28th Jul 20237:00 amRNSHalf Year Trading Update
15th Jun 20233:36 pmRNSResult of AGM
22nd May 20231:16 pmRNSNotice of AGM
3rd May 20232:42 pmRNSUpdate on Full Year Results
28th Apr 20231:36 pmRNSDirector/PDMR Share Dealing
27th Apr 20237:00 amRNSPreliminary Unaudited Results
19th Apr 202312:24 pmRNSHolding(s) in Company
23rd Mar 20237:00 amRNSHolding(s) in Company
14th Mar 20233:15 pmRNSHolding(s) in Company
30th Jan 20233:18 pmRNSHolding(s) in Company
27th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSFull Year Trading Update
22nd Dec 20227:00 amRNSHolding(s) in Company
21st Dec 20227:00 amRNSHolding(s) in Company
19th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAppointment of Non-Executive Directors
25th Nov 20224:41 pmRNSSecond Price Monitoring Extn
25th Nov 20224:35 pmRNSPrice Monitoring Extension
11th Nov 202211:05 amRNSSecond Price Monitoring Extn
11th Nov 202211:00 amRNSPrice Monitoring Extension
9th Nov 20223:33 pmRNSHolding(s) in Company
8th Nov 20222:06 pmRNSSecond Price Monitoring Extn
8th Nov 20222:00 pmRNSPrice Monitoring Extension
8th Nov 20227:00 amRNSDirector/PDMR Share Dealing
3rd Nov 20227:00 amRNSDirector/PDMR Share Dealing
31st Oct 20223:05 pmRNSDirector/PDMR Shareholding
28th Oct 20226:25 pmRNSDirector/PDMR Shareholding - Replacement
28th Oct 20223:25 pmRNSDirector/PDMR Shareholding
27th Oct 20222:06 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
27th Oct 20229:05 amRNSSecond Price Monitoring Extn
27th Oct 20229:00 amRNSPrice Monitoring Extension
27th Oct 20227:00 amRNSTrading Update and Board Changes
20th Oct 202211:12 amRNSHolding(s) in Company
19th Oct 20224:18 pmRNSHolding(s) in Company
15th Sep 20225:44 pmRNSHolding(s) in Company
7th Sep 20227:00 amRNSDirector/PDMR Share Dealing
30th Aug 20224:52 pmRNSHolding(s) in Company
23rd Aug 20225:02 pmRNSHolding(s) in Company
18th Aug 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.